ICTS

NANBIOSIS Launches Its Official Newsletter

By subscribing to our Newsletter, you will receive curated updates straight to your inbox.

We are pleased to announce the launch of the NANBIOSIS Newsletter, a new communication channel designed to keep our community up to date with the most relevant news and opportunities from our infrastructure.

By subscribing to our Newsletter, you will receive curated updates straight to your inbox every three months, featuring selected content you won’t want to miss. We value your time: we do not spam, and the Newsletter will only be sent to users who actively subscribe.

👉 If you wish to receive future editions, you can subscribe here.

Celebrating 10 Years of NANBIOSIS as an ICTS: Highlights of 2025

To mark the 10th anniversary of NANBIOSIS as a Unique Scientific and Technical Infrastructure (ICTS), our first Newsletter includes a selection of key highlights from 2025:

Featured News

NANBIOSIS Strengthens Internal Collaboration at the 2025 Networking Event in Cáceres
A networking event bringing together Units working in biomaterials, nanomedicine, and biomedical research to foster collaboration. Read the article.

Revalidated as a Unique Scientific and Technical Infrastructure (ICTS)
In November 2025, NANBIOSIS was revalidated as a Spanish ICTS, reaffirming its strategic role in cutting-edge innovation. Read the article.

Danish Students Visit NANBIOSIS Unit 28 (NanoImaging) at IBIMA-BIONAND
International students explored advanced nanoimaging technologies driving innovation in biomedical research. Read the article.

In addition to other interesting scientific highlights. You can read the entire newsletter here.

Stay connected and don’t miss future updates: subscribe to the NANBIOSIS Newsletter and follow the latest developments from our Units, researchers, and infrastructures.

And do not forget, this is the last week for our Open Call! More information here.

Mark your calendar and ready your proposals! The Call is open until the end of January 2026. You can access to it here.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Ready your proposals: Open Call starts on january

NANBIOSIS opens in January the 1st Competitive Open Call of 2026 for our “Cutting-Edge Biomedical Solutions” and services.

Last year we made two Open Calls, and it was about time to introduce you to the first call of 2026: offering you our discounts and preferential access during the entire month of January! You can access to it here.

Our publicly funded facilities and internationally renowned scientists will help you design and test biomedical solutions to your heart’s content. We are open to all interested national and international users who may come either from the public or the private sector. You can apply to use our services in two modalities: under the “Competitive Open Access” (within our two designated yearly calls) or by “Access on Demand”, your choice.

To make that happen, at least 20% of the capacity of the Units of NANBIOSIS is offered on the Competitive Open Access modality. The proposals granted under this modality will be prioritized according to criteria of scientific and technical quality and singularity. In addition, a 5% discount will be applied for those proposals that resort to at least one of our integrated services, the Cutting-Edge Biomedical Solutions. The call can be accessed here.

NANBIOSIS is a research infrastructure for Biomedicine included in the the Spanish Map of ICTS (Spanish for “Scientific and Technical Unique Infrastructures”), approved by the Spanish Ministerio de Ciencia, Innovación y Universidades.

There are 2 calls per year for Competitive Open Access that allow the prioritization of the best proposals. Click here to apply.

As stated, the next call will open on January 2026. The applications can be submitted throughout the whole month (due date January 31th). Access application forms submitted after that date will be processed under the “Access on Demand” modality.

Proposals granted in the Competitive Open Access modality must meet, at least, one of the circumstances listed in the access application form (“order request“), in order to demonstrate their scientific and technical quality or singularity.

Thus, for example, applications related to R&D projects funded through national or European calls are eligible. In addition, the proposals are required to use one of the NANBIOSIS “Cutting-Edge Biomedical Solutions”. That implies the interaction of at least two of our Units. The choice of said Units can be modified to your specific needs.

Mark your calendar and ready your proposals! The Call is open until the end of January 2026. You can access to it here.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Ready your proposals: Our Open Call starts on june

NANBIOSIS opens in June the 2nd Competitive Open Call of 2025 for our “Cutting-Edge Biomedical Solutions” and services.

Last January, as a belated Christmas present, we opened our 1st Open Call of 2025, and it was about time to introduce you to the second call in June: offering you our discounts and preferential access during the entire month of June!

Our publicly funded facilities and internationally renowned scientist will help you design and test biomedical solutions to your heart’s content. We are open to all interested national and international users who may come either from the public or the private sector. You can apply to use our services in two modalities: under the “Competitive Open Access” (within our two designated calls) or by “Access on Demand”, your choice.

To make that happen, at least 20% of the capacity of the Units of NANBIOSIS is offered on the Competitive Open Access modality. The proposals granted under this modality will be prioritized according to criteria of scientific and technical quality and singularity. In addition, a 5% discount will be applied for those proposals that resort to at least one of our integrated services, the Cutting-Edge Biomedical Solutions.

NANBIOSIS is a research infrastructure for Biomedicine included in the the Spanish Map of ICTS (Spanish for “Scientific and Technical Unique Infrastructures”), approved by the Spanish Ministerio de Ciencia, Innovación y Universidades.

There are 2 calls per year for Competitive Open Access that allow the prioritization of the best proposals. Click here to apply.

As stated, the next call will open on June 2025. The applications can be submitted throughout the whole month (due date June 30th). Access application forms submitted after that date will be processed under the “Access on Demand” modality.

Proposals granted in the Competitive Open Access modality must meet, at least, one of the circumstances listed in the access application form (“order request“), in order to demonstrate their scientific and technical quality or singularity.

Thus, for example, applications related to R&D projects funded through national or European calls are eligible. In addition, the proposals are required to use one of the NANBIOSIS “Cutting-Edge Biomedical Solutions”. That implies the interaction of at least two of our Units. The choice of said Units can be modified to your specific needs.

Mark your calendar and ready your proposals! The Call will be open until the end of June 2025.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Ready your proposals: Our Open Call starts on january 2025

NANBIOSIS opens in January the 1st Competitive Open Call of 2025 for our “Cutting-Edge Biomedical Solutions” and services.

Last year we opened two Competitive Calls: the first one happened in februrary 2024, and the second in june 2024. However, as a belated Christmas present, we would like to open this coming 2025 with our 1st Open Call of 2025 right away: offering you our discounts and preferential access as early as january!

Our publicly funded facilities and internationally renowned scientist will help you design and test biomedical solutions to your heart’s content. We are open to all interested national and international users who may come either from the public or the private sector. You can apply to use our services in two modalities: under the “Competitive Open Access” (within two designated calls) or by “Access on Demand”, your choice.

To make that happen, at least 20% of the capacity of the Units of NANBIOSIS is offered on the Competitive Open Access modality. The proposals granted under this modality will be prioritized according to criteria of scientific and technical quality and singularity. In addition, a 5% discount will be applied for those proposals that resort to at least one of our integrated services, the Cutting-Edge Biomedical Solutions.

NANBIOSIS is a research infrastructure for Biomedicine included in the the Spanish Map of ICTS (Spanish for “Scientific and Technical Unique Infrastructures”), approved by the Spanish Ministerio de Ciencia, Innovación y Universidades.

There are 2 calls per year for Competitive Open Access that allow the prioritization of the best proposals. Click here to apply.

As stated, the next call will open on January 2025. The applications can be submitted throughout the whole month (due date January 31th). Access application forms submitted after that date will be processed under the “Access on Demand” modality.

Proposals granted in the Competitive Open Access modality must meet, at least, one of the circumstances listed in the access application form (“order request“), in order to demonstrate their scientific and technical quality or singularity.

Thus, for example, applications related to R&D projects funded through national or European calls are eligible. In addition, the proposals are required to use one of the NANBIOSIS “Cutting-Edge Biomedical Solutions”. That implies the interaction of at least two of our Units. The choice of said Units can be modified to your specific needs.

Mark your calendar and ready your proposals! The Call will be open until the end of January 2025.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

NANBIOSIS receives the support of the Spanish Research Agency (Ministry of Science and Innovation) financing the NANBIO-ACCESS project, in the 2022 call for Excellence Research Networks.

Today has been published the Resolution of the Presidency of the State Research Agency of the Spanish Ministry for Science and Innovation granting fund for the selected projects in the 2022 call for “RESEARCH NETWORKS” within the framework of the State Program to Promote Scientific-Technical Research and its Transfer, of the State Research Plan Scientific, Technical and Innovation

The final resolution proposal was issued on June 21, 2023, once the hearing process has been completed and prior acceptance by the interested parties.

The two years lasting project 2021-2023RED2022-134685-I “NANBIO-ACCESS” was among the selected proposals.

The main goals pursued by the projects are:

1. Promote and consolidate the offer of the NANBIOSIS strategic services, which target advanced challenges in biomedical research: our Cutting-Edge Biomedical Solutions.

2. Promote the open and competitive access to NANBIOSIS services and, especially, to our strategic services.

3. Strengthen NANBIOSIS communication tools and enhance internationalization capabilities.

The proposed activities address the coordination within NANBIOSIS and the complementarity of the capacities of its units, optimizing its resources. Actions are especially proposed to promote the participation of NANBIOSIS nodes and units to the “Cutting-Edge Biomedical Solutions” program.